FTZ Fund
VC Fund
Shanghai, China
FTZ Fund is a VC fund in Shanghai focused on Biotechnology and Manufacturing. Shanghai Free Trade Zone Equity Fund (FTZ Fund) is the first Free Trade Zone fund in China. It was set up against the backdrop of the State Council’s initiatives to build China (Shanghai) Pilot Free Trade Zone and to deepen reform and opening-up. The fund follows the strategic guidance of the central, municipal and district-level governments,facilitates system innovation, financial innovation, and opening-up of the service sector, cultivates functional projects, encourages new economy, and boosts Shanghai’s strategic building of international economic center, international financial center, international shipping center, international trade center and international innovation center. Established on 28 December 2014, the Fund has an initial size of 5 billion CNY with a maturity of 5-7 years. It is co-founded by Shanghai Lujiazui (Group) Co., Ltd., Shanghai Waigaoqiao (Group) Co., Ltd., Shanghai Airport Authority, China Cinda Asset Management Co., Ltd., and China Orient Asset Management Corporation. Located in China (Shanghai) Pilot Free Trade Zone, the FTZ fund is able to leverage resources in both the domestic and the international markets, integrate resources among governments, industries and companies, and explore mutually beneficial investment opportunities. It mainly invests in the equity projects in leading areas in the FTZ, such as logistics, cross-border e-commerce, smart manufacturing biopharmaceuticals, IT, culture, and Internet finance. It helps to push forward pilot projects on cross-border investment and financing, and reforms of state-owned enterprises (SOEs). The fund also invests in property projects to upgrade urban development of the FTZ.
- Total investments:
- 29
- Last investment:
- Lead investor:
- 31%
Last updated:
For AI agents: llms.txt
Industries FTZ Fund invests in
Stages FTZ Fund invests in
Countries FTZ Fund invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Hao Lu
|
|||
|
Zhou Siliang
|
|||
3 more contacts available
Investment Focus
Industry
- Biotechnology 7 (24%)
- Manufacturing 7 (24%)
- Health Care 6 (21%)
- Semiconductor 5 (17%)
- Medical 4 (14%)
Stage
- Series B 10 (34%)
- Series A 5 (17%)
- Series C 5 (17%)
- Series D 4 (14%)
- Seed 1 (3%)
Country
- China 23 (79%)
- United States 2 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Hao Lu
Chief Investment Officer
|
Chief Investment Officer | Total investments: 0 | Find email | |
|
Zhou Siliang
Founder & Chairman
|
Founder & Chairman | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Tejin Intelligence
|
Tejin Intelligence is deeply involved in radio sensing and spectrum big data analysis technology, and is dedicated to providing the world's leading low-altitude safety management and control solutions, assisting in the development of new ground-air integrated three-dimensional security infrastructure for smart cities, and striving for refinedmanagement of urban low-altitude airspace. | $13.8M / Series B / May 20, 2024 | |
SimChip Technology
|
SimChip is a chip design company that provides research, development, production, and application of high-end analog integrated circuits. | $14.1M / Series B / Dec 29, 2023 | |
Susheng Biotech
|
Susheng Biotech specialized in the research and commercialization of regenerative sports medicine. Cutting-edge technical solutions, such as bio-regenerative materials, address the clinical pain points of soft tissue repair and regeneration in sports medicine. | Seed / Jul 10, 2023 | |
Li Krypton Technology
|
Likrypton Technology provides product research and development in key areas of new energy vehicles and autonomous driving. | $58.2M / Series B / Apr 06, 2023 | |
PhaBuilder
|
PhaBuilder is a platform-based & product-based company with advanced technology in synthetic biology, focusing on the transformation and engineering application of halophilic microbes.PhaBuilder was founded in February 2021 by Professor Guoqiang Chen, director of the Center for Synthesis and Systems Biology at Tsinghua University. It mainlyuses the cutting-edge "Next Generation Industrial Biotechnology(NGIB)" to develop and produce a variety of high-value-added products such as PHA - a biodegradable material, ectoine - a pharmaceutical intermediate, and cadaverine - a Nylon 56 precursor. PhaBuilder currently has two PHA plants under construction - the synthetic biology intelligent development plant in Beijing China-Germany Industrial Park and the 10 kt/annum plant in Yichang, Hubei Province. It also plans to build up 3-5 large-scale production bases throughout China within five years. At present, PhaBuilder has completed two rounds of financing, raising around 300 million yuan in total. The investors include Sequoia Capital, China State-owned Enterprise Mixed Ownership Reform Fund, and GRC SinoGreen Fund, etc. In the future, PhaBuilder will constantly promote synthetic biotechnology to deeply integrate with people's lives and upgrade the intelligent biological manufacturing industry, in order to achieve PhaBuilder's core mission of "Using microbes to change the world and build a green future". | $53.3M / Series A / Feb 02, 2023 | |
Yuxin Electronics
|
Yuxin Electronics is a high-performance analog and mixed-signal device integrated circuit design service provider. | Series B / Jan 17, 2023 | |
Bangyao Biological
|
Bangyao Biological is a gene pharmaceutical company focusing on biological research activities and pharmaceutical development. | Series B / Nov 14, 2022 | |
Ark Biosciences
|
Ark Biosciences is a biopharmaceutical company that is dedicated to the discovery and development of innovative therapeutics to address unmet medical need, especially in the area of respiratory viral infection and viral hepatitis, for global and China market. We strive to build a science-driven biopharmaceutical company that aims to be a leader inantiviral drug discovery and development. To achieve so, we aspire for the excellence of science and be innovative. We operate with a razor-sharp focus and aggressiveness with a timely and cost efficient manner. We create a healthy and rewarding work environment for employees, and seek a superior rate of return for investors and partners. | Series D / Jul 14, 2022 | |
Iluvatar CoreX
|
Iluvatar CoreX is a leading developer of high-performance computing solutions including System-on-a-Chip (SoC) chipset and its proprietary software platform. The company was founded in December 2015 by a group of world-class software and semiconductor experts from Silicon Valley and China which have been working together for more than two decadesin the field of AI at companies like Oracle, AMD/ATI and Fujitsu.Iluvatar has assembled a group of experts in system software, computing middleware, algorithms, parallel processing, GPU, AI, and IC design to develop end-to-end high-performance processing solutions in-house. Iluvatar solution addresses the limitations on computing power needs for AI applications by creatively exploiting the advantages of ultra-large-scale parallel computing architecture, with its general-purpose, standard, and high-performance cloud computing SoC solution (GP-GPU). Iluvatar solution is already proven. For the last 3 years, the company has been shipping its new generation of data processing software technology (soft silicon) named SkyDiscovery. | $148.8M / Series C / Jul 13, 2022 | |
Ferrotec
|
Ferrotec is a diversified technology company with a worldwide presence in a broad array of end products, manufacturing systems, and industries. They provide there customers with advanced material, component, and assembly solutions that make their products work better, more precisely, and more reliably.Founded on a technology core of Ferrofluidmagnetic liquid and Ferrofluidic® sealing products, there company and there product portfolio have grown to meet the evolving needs of our customers. Ferrotec is now a global enterprise characterized by substantial intercompany cooperation in research, manufacturing and marketing of products. | $74.6M / Post-IPO Equity / Jun 30, 2022 | |
| See all 29 investments → | |||
Co-Investors
Hillhouse Investment
4 deals together
Oriental Fortune Capital
4 deals together
China Internet Investment Fund
3 deals together
CICC
3 deals together
Hillhouse Investment
3 deals together
Vision Plus Capital
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does FTZ Fund invest in?
FTZ Fund invests primarily in Biotechnology, Manufacturing and Health Care startups, most often at Series B and Series A stage. Most of the 29 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact FTZ Fund?
Public channels for FTZ Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at FTZ Fund?
The team at FTZ Fund includes Hao Lu (Chief Investment Officer) and Zhou Siliang (Founder & Chairman). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
